Bellerophon Therapeutics, Inc. (BLPH) financial statements (2022 and earlier)

Company profile

Business Address 184 LIBERTY CORNER ROAD, SUITE 302
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments24,73647,5579,87416,64528,82314,4536,260
Cash and cash equivalents24,73647,5579,87416,64528,82314,4536,260
Restricted cash and investments103103103101402150 
Other undisclosed current assets6204204056506,35511,90223,192
Total current assets:25,45948,08010,38217,39635,58026,50529,452
Noncurrent Assets
Operating lease, right-of-use asset8631,504 
Property, plant and equipment671693166641,0261,3991,799
Restricted cash and investments300300300300150307457
Other noncurrent assets186186  541,4916,701
Other undisclosed noncurrent assets  2,110    
Total noncurrent assets:1,4162,1592,7269641,2303,1978,957
TOTAL ASSETS:26,87550,23913,10818,36036,81029,70238,409
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,9036,0304,8093,7685,2943,7295,100
Accounts payable1,1923,7253,1062,7553,8532,8071,613
Accrued liabilities1,7112,3051,7031,0131,4419223,487
Due to related parties     193148
Other undisclosed current liabilities2,1494,4032,7753,7711,7852,5732,825
Total current liabilities:5,05210,4337,5847,5397,0796,4958,073
Noncurrent Liabilities
Long-term debt and lease obligation203956     
Operating lease, liability203956 
Other undisclosed noncurrent liabilities(202)(355)1,9336,96532,3255,215 
Total noncurrent liabilities:2041,5571,9336,96532,3255,215 
Total liabilities:5,25611,9909,51714,50439,40411,7108,073
Stockholders' equity
Stockholders' equity attributable to parent21,61938,2493,5913,856(2,594)17,99230,336
Common stock959546587569317131
Additional paid in capital253,771252,645193,308179,765176,151142,167130,902
Accumulated other comprehensive loss    (4) (19)
Accumulated deficit(232,247)(214,491)(189,763)(176,496)(179,310)(124,492)(100,678)
Total stockholders' equity:21,61938,2493,5913,856(2,594)17,99230,336
TOTAL LIABILITIES AND EQUITY:26,87550,23913,10818,36036,81029,70238,409

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Other Operating Income)
      1,667
Cost of revenue
(Cost of Goods and Services Sold)
(100)(100)     
Gross profit:(100)(100)    1,667
Operating expenses(20,161)(26,276)(17,473)(27,880)(24,599)(23,757)(48,235)
Other undisclosed operating income100100     
Operating loss:(20,161)(26,276)(17,473)(27,880)(24,599)(23,757)(46,568)
Nonoperating income (expense)5(250)39737818495109
Investment income, nonoperating  39737818495109
Interest and debt expense (300)  (111)  
Loss from continuing operations before equity method investments, income taxes:(20,156)(26,826)(17,076)(27,502)(24,526)(23,662)(46,459)
Other undisclosed income (loss) from continuing operations before income taxes600(27)2,00824,877(30,292)(590) 
Loss from continuing operations before income taxes:(19,556)(26,853)(15,068)(2,625)(54,818)(24,252)(46,459)
Income tax benefit1,8002,1251,8015,439 438 
Net income (loss) available to common stockholders, diluted:(17,756)(24,728)(13,267)2,814(54,818)(23,814)(46,459)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(17,756)(24,728)(13,267)2,814(54,818)(23,814)(46,459)
Other comprehensive income (loss)   4(4)19(19)
Comprehensive income (loss), net of tax, attributable to parent:(17,756)(24,728)(13,267)2,818(54,822)(23,795)(46,478)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: